GO
Loading...

Enter multiple symbols separated by commas

Government Agencies FDA

More

  • Weighing the risks of ibuprofen Friday, 10 Jul 2015 | 1:56 PM ET
    Weighing the risks of ibuprofen

    Discussing safer alternatives to ibuprofen after the FDA warnings, with Dr. Devi Nampiaparampil, NYU School of Medicine. "All of the alternatives have risks," she explains.

  • July 10- The U.S. food and Drug Administration said it was strengthening an existing warning label that non-aspirin, non-steroidal anti-inflammatory drugs increase the chance of a heart attack or stroke. NSAIDs are used to treat pain and fever from medical conditions such as arthritis, menstrual cramps, headaches, colds, and the flu, and some of the better-known...

  • FDA extends calorie count deadline for restaurants Friday, 10 Jul 2015 | 9:00 AM ET
    FDA extends calorie count deadline for restaurants

    The FDA gives restaurants more time to put calorie counts on their menus.

  • MUMBAI/ LONDON, July 10- The U.S. Food and Drug Administration and the World Health Organisation have intensified investigations into India's clinical research firms, industry officials said, after recent probes revealed two leading firms had violated standards. The scrutiny is likely to further hurt India's reputation as a global pharmaceutical hub, as it...

  • FDA strengthens warnings on painkillers Friday, 10 Jul 2015 | 7:00 AM ET
    FDA strengthens warnings on painkillers

    FDA Strengthens Heart Safety Warnings on Painkillers.

  • Before you pop that ibuprofen, read new warnings Thursday, 9 Jul 2015 | 7:35 PM ET
    Ibuprofen tablets

    The FDA is strengthening its warnings about painkillers like ibuprofen, saying they do raise the risk of heart attack or stroke.

  • WASHINGTON, July 9- An advisory panel to the U.S. Food and Drug Administration effectively supported approval of Eli Lilly& Co's experimental lung cancer drug necitumumab on Thursday but recommended measures be taken to mitigate the drug's risks. The panel did not officially vote but an informal poll taken by the FDA indicated most members believe the...

  • Novartis news goes straight to the heart Wednesday, 8 Jul 2015 | 6:00 AM ET
    Novartis news goes straight to the heart

    Novartis wins FDA approval for new combination drug Entresto to treat heart failure.

  • July 7- Novartis AG on Tuesday won U.S. approval for its keenly awaited new heart failure drug Entresto earlier than expected, boosting hopes for a medicine tipped by analysts to reap billions of dollars in annual sales. Novartis is looking to Entresto to help revive its fortunes as the blood pressure pill Diovan- a major source of the company's profits in the past-...

  • FDA approves Novartis' heart failure drug Tuesday, 7 Jul 2015 | 4:47 PM ET

    July 7- The U.S. Food and Drug Administration said it approved Novartis AGs' drug to treat heart failure.

  • Seprafilm, developed by Genzyme, is used to reduce abnormal internal scarring following surgery, by separating tissues and organs while they heal. The FDA and Genzyme, which was bought by Sanofi in 2011, were not immediately available for comment. FDA database of Manufacturer and User Facility Device Experience cites at least nine reports that link Seprafilm...

  • July 7- Consumer watchdog Public Citizen said it petitioned the U.S. health regulators to withdraw approval of Sanofi SA's Seprafilm and order a recall, saying the surgical implant has been associated with side effects including death. Seprafilm, developed by Genzyme, is used to reduce abnormal internal scarring following surgery, by separating tissues and...

  • July 2- Vertex Pharmaceuticals Inc's unique combination therapy for a rare lung disorder was given the green light by U.S. health regulators, extending the company's reach to the most common form of genetic mutation responsible for cystic fibrosis. Orkambi, a combination of Vertex's approved drug Kalydeco and a new compound called lumacaftor, is intended for...

  • July 2- Vertex Pharmaceuticals Inc's combination therapy for a rare lung disorder was approved by U.S. health regulators, extending the company's reach to now treat the most common form of genetic mutation responsible for cystic fibrosis. Orkambi, a combination of Vertex's approved drug Kalydeco and a new compound called lumacaftor, is intended for patients...

  • July 1- Bayer Healthcare said on Wednesday the U.S. Food and Drug Administration approved using transvaginal ultrasound as an alternate test to confirm if the company's Essure permanent birth control device has been placed properly. But since its approval in 2002, women using the device have sent the FDA more than 5,000 complaints, ranging from pain and...

  • June 30- The U.S. Food and Drug Administration said it is seeking additional data and comments on liquid nicotine as it considers warning the public about the dangers of its exposure amid a rise in electronic cigarette use. More Americans are using e-cigarettes and other vaporizing devices than a year ago, a Reuters/ Ipsos poll showed in June.

  • In their June 25 lawsuit, Yale University's Global Health Justice Partnership and the Treatment Action Group, an AIDS non-profit, said doctors and patients deserve more information about the "enormously costly" drugs Harvoni and Sovaldi to make informed decisions about whether to use them. The plaintiffs said Gilead ignored its request for the trial data,...

  • June 26- Animal health drugmaker Aratana Therapeutics Inc said its experimental appetite-stimulating drug was found effective in dogs in a pivotal study. The company said it plans to submit the results to the U.S. Food and Drug Administration as it seeks marketing approval, and expects to start commercializing the drug in 2016.. The Kansas City- based...

  • Zoetis halted for volatility on takeover report Thursday, 25 Jun 2015 | 3:58 PM ET
    Zoetis

    Animal health behemoth Zoetis was halted for volatility on Thursday.

  • June 24- The U.S. Food and Drug Administration said it would discuss the safety and effectiveness of Bayer AG's controversial contraceptive device, Essure, in a public panel meeting after receiving more than 5000 complaints, including those of deaths and pregnancies. The FDA approved the device in November 2002. The FDA said it plans to hold a meeting of the...